DR info

臨床試験数 : 18 / 薬物数 : 43 - (DrugBank : 14) / 標的遺伝子数 : 17 - 標的パスウェイ数 : 82

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

AP1903
   Bellicum Pharmaceuticals, Inc.
      2017   Phase 2   EUCTR2014-000584-41-ES   Italy;Spain;United Kingdom;
      2017   Phase 1;Phase 2   EUCTR2016-003226-16-IT   Italy;
      2014   Phase 1;Phase 2   EUCTR2014-000584-41-IT   Italy;Spain;United Kingdom;
AP1903 A594
   Bellicum Pharmaceuticals, Inc.
      -   Phase 2   EUCTR2014-000584-41-GB   Italy;Spain;United Kingdom;
Actimmune Registry
   InterMune
      2002   -   NCT00043329   United States;
BPX-501 T cells
   Bellicum Pharmaceuticals
      2014   Phase 2   NCT02065869   Germany;Italy;Spain;United Kingdom;United States;
      2014   Phase 1/Phase 2   NCT03301168   Italy;United States;
BPX-501 cells
   Bellicum Pharmaceuticals, Inc.
      2017   Phase 2   EUCTR2014-000584-41-ES   Italy;Spain;United Kingdom;
      2014   Phase 1;Phase 2   EUCTR2014-000584-41-IT   Italy;Spain;United Kingdom;
      -   Phase 2   EUCTR2014-000584-41-GB   Italy;Spain;United Kingdom;
Busulfan
   Masonic Cancer Center, University of Minnesota
      2008   Phase 2/Phase 3   NCT00775931   United States;
Busulfan, Cyclophosphamide, Thymoglobulin, Fludarabine (Conditioning regimen)
   Tehran University of Medical Sciences
      2009   Phase 2/Phase 3   NCT01087398   Iran, Islamic Republic of;
CALD HR-D (High-Risk, Regimen C)
   Masonic Cancer Center, University of Minnesota
      2014   Phase 2   NCT02171104   United States;
CALD HR-D (High-Risk, Regimen D)
   Masonic Cancer Center, University of Minnesota
      2014   Phase 2   NCT02171104   United States;
CALD SR-A (Standard-Risk, Regimen A)
   Masonic Cancer Center, University of Minnesota
      2014   Phase 2   NCT02171104   United States;
CALD SR-B (Standard-Risk, Regimen B)
   Masonic Cancer Center, University of Minnesota
      2014   Phase 2   NCT02171104   United States;
CD34+ enriched, T Cell Depleted donor stem cell product
   Christopher Dvorak
      2010   -   NCT01200017   United States;
Calcitriol
   FDA Office of Orphan Products Development
      1999   Phase 3   NCT00004402   -
Campath, Busulfan, Clofarabine
   Masonic Cancer Center, University of Minnesota
      2007   Phase 2   NCT00638820   United States;
Campath-1H
   Masonic Cancer Center, University of Minnesota
      2008   Phase 2/Phase 3   NCT00775931   United States;
Cyclophosphamide
   Masonic Cancer Center, University of Minnesota
      2008   Phase 2/Phase 3   NCT00775931   United States;
Cyclophosphamide 30
   Columbia University
      2002   Phase 2/Phase 3   NCT01019876   United States;
Cyclophosphamide 40
   Columbia University
      2002   Phase 2/Phase 3   NCT01019876   United States;
Cyclosporin, Methotrexate (GVHD prophylaxis)
   Tehran University of Medical Sciences
      2009   Phase 2/Phase 3   NCT01087398   Iran, Islamic Republic of;
Fludarabine
   Columbia University
      2002   Phase 2/Phase 3   NCT01019876   United States;
Fludarabine monophosphate
   Masonic Cancer Center, University of Minnesota
      2008   Phase 2/Phase 3   NCT00775931   United States;
Hematopoetic Stem Cell Transplantation
   University of Pittsburgh
      2012   -   NCT03333200   United States;
IMD Preparative Regimen
   Masonic Cancer Center, University of Minnesota
      2014   Phase 2   NCT02171104   United States;
Interferon gamma-1b
   Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
      2016   Phase 2   NCT02666768   United States;
Marrow graft transplantation
   Masonic Cancer Center, University of Minnesota
      2008   Phase 2/Phase 3   NCT00775931   United States;
Miltenyi Biotec CliniMACS
   St. Jude Children's Research Hospital
      2004   -   NCT00145587   United States;
Osteopetrosis Haploidentical Only Preparative Regimen
   Masonic Cancer Center, University of Minnesota
      2014   Phase 2   NCT02171104   United States;
Osteopetrosis Only Preparative Regimen
   Masonic Cancer Center, University of Minnesota
      2014   Phase 2   NCT02171104   United States;
RP-L401
   Rocket Pharmaceuticals Inc.
      2021   Phase 1   NCT04525352   United States;
RhPTH
   University of Chicago
      2003   Phase 1   NCT00145886   United States;
Rimiducid
   Bellicum Pharmaceuticals
      2014   Phase 2   NCT02065869   Germany;Italy;Spain;United Kingdom;United States;
      2014   Phase 1/Phase 2   NCT03301168   Italy;United States;
   Bellicum Pharmaceuticals, Inc.
      2017   Phase 2   EUCTR2014-000584-41-ES   Italy;Spain;United Kingdom;
      -   Phase 2   EUCTR2014-000584-41-GB   Italy;Spain;United Kingdom;
Rivogenlecleucel
   Bellicum Pharmaceuticals, Inc.
      -   Phase 2   EUCTR2014-000584-41-GB   Italy;Spain;United Kingdom;
Rivogenleucleucel
   Bellicum Pharmaceuticals, Inc.
      2017   Phase 2   EUCTR2014-000584-41-ES   Italy;Spain;United Kingdom;
Stem Cell Transplantation
   Masonic Cancer Center, University of Minnesota
      2014   Phase 2   NCT02171104   United States;
   St. Jude Children's Research Hospital
      2004   -   NCT00145587   United States;
   Tehran University of Medical Sciences
      2009   Phase 2/Phase 3   NCT01087398   Iran, Islamic Republic of;
Stem Cell or Umbilical Cord Blood Transplantation
   Masonic Cancer Center, University of Minnesota
      2007   Phase 2   NCT00638820   United States;
Systemic chemotherapy and antibodies
   St. Jude Children's Research Hospital
      2004   -   NCT00145587   United States;
Total Lymphoid Irradiation
   Masonic Cancer Center, University of Minnesota
      2007   Phase 2   NCT00638820   United States;
Umbilical cord blood transplantation
   Masonic Cancer Center, University of Minnesota
      2008   Phase 2/Phase 3   NCT00775931   United States;